INVO Fertility, Inc. (IVF)
- Previous Close
1.9000 - Open
1.8800 - Bid 1.8600 x 500
- Ask 2.0900 x 100
- Day's Range
1.8600 - 2.2002 - 52 Week Range
1.3800 - 17.0400 - Volume
733,713 - Avg. Volume
2,208,585 - Market Cap (intraday)
2.217M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-30.1900 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
INVO Fertility, Inc., a life science portfolio company, develops clinical stage assets to treat patients with fertility, oncology, and autoimmune diseases. The company operates in two divisions, NAYA Women's Health and NAYA Therapeutics. Its lead product includes NY-303, a GPC3-targeted FLEX-NK bispecific antibody that is in Phase I/II clinical trials for hepatocellular carcinoma, as well as solid and pediatric tumors; and NY-338, a CD38-targeted FLEX-NK bispecific antibody for multiple myeloma and autoimmune diseases. The company also offers INVOcell, a a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was formerly known as NAYA Biosciences, Inc. and changed its name to INVO Fertility, Inc. in April 2025. INVO Fertility, Inc. was founded in 2007 and is based in Sarasota, Florida.
nayabiosciences.comRecent News: IVF
View MorePerformance Overview: IVF
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IVF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IVF
View MoreValuation Measures
Market Cap
2.22M
Enterprise Value
41.75M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.10
Price/Book (mrq)
--
Enterprise Value/Revenue
6.39
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-14.86M
Diluted EPS (ttm)
-30.1900
Balance Sheet and Cash Flow
Total Cash (mrq)
1.53M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--